List of Aspruzyo Sprinkle drug patents

Aspruzyo Sprinkle is owned by Spil.

Aspruzyo Sprinkle contains Ranolazine.

Aspruzyo Sprinkle has a total of 2 drug patents out of which 0 drug patents have expired.

Aspruzyo Sprinkle was authorised for market use on 28 February, 2022.

Aspruzyo Sprinkle is available in granules, extended release;oral dosage forms.

The generics of Aspruzyo Sprinkle are possible to be released after 24 January, 2038.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10898444 SPIL Extended release multiparticulates of ranolazine
Jan, 2038

(14 years from now)

US11510878 SPIL NA
Jan, 2038

(14 years from now)

Drugs and Companies using RANOLAZINE ingredient

Market Authorisation Date: 28 February, 2022

Treatment: NA


More Information on Dosage

ASPRUZYO SPRINKLE family patents


United States




European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in